ABCAM PLC Directorate Change (0595Z)
May 19 2021 - 1:00AM
UK Regulatory
TIDMABC
RNS Number : 0595Z
ABCAM PLC
19 May 2021
19 May 2021
ABCAM PLC
("Abcam" or "the Company")
Directorate Change
Abcam plc announces that, after seven years with the Company,
Lady Louise Patten has retired from her roles as Non-executive
Director, Senior Independent Director and Chair of the Remuneration
Committee. Giles Kerr, who joined the Board in 2018, will become
Senior Independent Director with immediate effect. Mara Aspinall,
who joined the Board in 2015, and is on the Remuneration Committee
will chair the Remuneration Committee in the interim.
Peter Allen, Chairman of Abcam, said:
"We would like to sincerely thank Louise for her contribution to
Abcam since joining seven years ago. Abcam has enjoyed remarkable
success during this period and we wish Louise every future
success."
Louise Patten added:
"I would like to thank Peter and the Board. It has been a
pleasure to be part of one of the strongest growth stories in the
UK life sciences market. I believe the team is well set for
continued success."
- Ends -
Abcam + 44 (0) 1223 696 000
James Staveley, Vice President, Investor Relations
Numis - Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000
Garry Levin / Freddie Barnfield / Duncan Monteith
J.P. Morgan Cazenove - Joint Corporate Broker + 44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
Morgan Stanley - Joint Corporate Broker + 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting + 44 (0) 20 3727 1000
Ben Atwell / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Group offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Some two-thirds of the world's 750,000 life science researchers
use Abcam's antibodies, reagents, biomarkers and assays. By
actively listening to and collaborating with these researchers, the
Group continuously advances its portfolio to address their needs. A
transparent programme of customer reviews and datasheets, combined
with an industry-leading validation initiative, gives researchers
increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 140 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
Please visit www.abcam.com or www.abcamplc.com to find out
more.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation
statements of targets, plans, objectives or goals for future
operations, including those related to the make-up of Abcam's Board
of Director's membership, Abcam's Board of Director's structure and
the structure and membership of the Remuneration Committee,
statements regarding the assumptions underlying or relating to such
statements; statements about Abcam's portfolio and ambitions, as
well as statements that include the words "expect," "intend, "
"plan," "believe," "project," "forecast," "estimate," "may,"
"should," "anticipate" and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation: a regional or
global health pandemic, including the novel coronavirus
("COVID-19"), which has adversely affected elements of our
business, could severely affect our business, including due to
impacts on our operations and supply chains; challenges in
implementing our strategies for revenue growth in light of
competitive challenges; developing new products and enhancing
existing products, adapting to significant technological change and
responding to the introduction of new products by competitors to
remain competitive; failing to successfully identify or integrate
acquired businesses or assets into our operations or fully
recognize the anticipated benefits of businesses or assets that we
acquire; if our customers discontinue or spend less on research,
development, production or other scientific endeavors; failing to
successfully use, access and maintain information systems and
implement new systems to handle our changing needs; cyber security
risks and any failure to maintain the confidentiality, integrity
and availability of our computer hardware, software and internet
applications and related tools and functions; failing to
successfully manage our current and potential future growth; any
significant interruptions in our operations; if our products fail
to satisfy applicable quality criteria, specifications and
performance standards; failing to maintain our brand and
reputation; our dependence upon management and highly skilled
employees and our ability to attract and retain these highly
skilled employees; and the important factors discussed under the
caption "Risk Factors" in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZGMKRRGGMZM
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024